Owing to the advances in understanding the glioblastoma tumor microenvironment, inhibitor of apoptosis protein (IAP) survivin has been proposed as an anticancer target for malignancies, including gliomas, for decades, and appears to be a considerable adjunct to GBM therapy [28]. This evidence concerns the gene BIRC5 and central nervous system cancer.